iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Up 114.6% in August

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 33,524 shares, a growth of 114.6% from the July 30th total of 15,622 shares. Based on an average daily volume of 50,553 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

A hedge fund recently raised its stake in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. increased its holdings in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) by 8.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned about 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent reporting period.

iShares Genomics Immunology and Healthcare ETF Stock Performance

NYSEARCA IDNA opened at $39.29 on Monday. The business has a fifty day moving average price of $34.53 and a 200 day moving average price of $31.34. The company has a market cap of $231.81 million, a P/E ratio of 14.76 and a beta of 0.93. iShares Genomics Immunology and Healthcare ETF has a one year low of $22.12 and a one year high of $41.49.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.